Josh Woolley

Yeah.

So in recent years, um, through sort of the people around me, um, including, um, Josh Woolley, who is my spouse and, uh, collaborator, I have-- I sort of couldn't avoid thinking about psychedelic therapy.

And psychedelic therapy has really, um, exploded in popularity.

The interest in it from a mental health point of view, um, has grown exponentially over the last decade.

But rather than acknowledging the futility here and just giving up as they characterize some other author's prescriptions, this group of researchers say that the field has not tried sufficiently aggressive approaches.

So to discuss some of those approaches and the questions around blinding in general, I spoke with Joshua Woolley, one of the researchers behind that paper So we all know the problem of blinding in psychedelic trials is pretty endemic, and you and your co-authors have talked about a sort of masking nihilism, where people in the field have almost kinda given up on the idea of blinding these studies.

We've tried things like what, like niacin, diphenhydramine, and sort of different study designs, and no one seems to have cracked it.

So what are you and your co-authors proposing in this new article?